Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorXie, J.en
dc.contributor.authorShen, K.en
dc.contributor.authorLenchine, R.en
dc.contributor.authorGethings, L.en
dc.contributor.authorTrim, P.en
dc.contributor.authorSnel, M.en
dc.contributor.authorZhou, Y.en
dc.contributor.authorKenney, J.en
dc.contributor.authorKamei, M.en
dc.contributor.authorKochetkova, M.en
dc.contributor.authorWang, X.en
dc.contributor.authorProud, C.en
dc.identifier.citationInternational Journal of Cancer, 2018; 142(9):1865-1877en
dc.description.abstractEukaryotic elongation factor 2 kinase (eEF2K) negatively regulates the elongation phase of mRNA translation and hence protein synthesis. Increasing evidence indicates that eEF2K plays an important role in the survival and migration of cancer cells and in tumor progression. As demonstrated by two-dimensional wound-healing and three-dimensional transwell invasion assays, knocking down or inhibiting eEF2K in cancer cells impairs migration and invasion of cancer cells. Conversely, exogenous expression of eEF2K or knocking down eEF2 (the substrate of eEF2K) accelerates wound healing and invasion. Importantly, using LC-HDMSE analysis, we identify 150 proteins whose expression is decreased and 73 proteins which are increased upon knocking down eEF2K in human lung carcinoma cells. Of interest, 34 downregulated proteins are integrins and other proteins implicated in cell migration, suggesting that inhibiting eEF2K may help prevent cancer cell mobility and metastasis. Interestingly, eEF2K promotes the association of integrin mRNAs with polysomes, providing a mechanism by which eEF2K may enhance their cellular levels. Consistent with this, genetic knock down or pharmacological inhibition of eEF2K reduces the protein expression levels of integrins. Notably, pharmacological or genetic inhibition of eEF2K almost completely blocked tumor growth and effectively prevented the spread of tumor cells in vivo. High levels of eEF2K expression were associated with invasive carcinoma and metastatic tumors. These data provide the evidence that eEF2K is a new potential therapeutic target for preventing tumor metastasis.en
dc.description.statementofresponsibilityJianling Xie, Kaikai Shen, Roman V. Lenchine, Lee A. Gethings, Paul J. Trim, Marten F. Snel, Ying Zhou, Justin W. Kenney, Makoto Kamei, Marina Kochetkova, Xuemin Wang, and Christopher G. Prouden
dc.rights© 2017 UICCen
dc.subjecteEF2K; translation; metastasis; migration; lung canceren
dc.titleEukaryotic elongation factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasisen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidTrim, P. [0000-0001-8734-3433]en
dc.identifier.orcidSnel, M. [0000-0002-8502-7274]en
dc.identifier.orcidKamei, M. [0000-0002-1438-0783]en
dc.identifier.orcidProud, C. [0000-0003-0704-6442]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.